3 results about "Apelin" patented technology

The invention discloses a biomarker combination for predicting PCI postoperative LVR of an STEMI patient and application of the biomarker combination, and belongs to the technical field of biology. The research discovers that in a left ventricular remodeling (LVR) group and a non-left ventricular remodeling group after percutaneous coronary intervention (PCI) of a patient suffering from acute ST segment elevation type myocardial infarction (STEMI), a left ventricular endocardial lower myocardial overall longitudinal strain (GLS internal) value, a lung B-line integral, a serum sFRP5 level and Apelin-13 show significant differences. Through combined prediction analysis, it is found that the GLS internal value, the lung B-line integral, the serum sFRP5 and the Apelin-13 have excellent prediction performance on whether the LVR occurs after the PCI operation of the STEMI patient or not, high-risk groups, suffering from the LVR after the PCI operation, of the STEMI patient can be accurately and efficiently recognized, intervention is conducted as soon as possible, and the life quality of the patient is expected to be improved.

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and / or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

The invention provides an Apelin and HBD3 delivery system based on hydrogel and engineering extracellular vesicles as well as a preparation method and application of the Apelin and HBD3 delivery system, and belongs to the technical field of medicines. The preparation method comprises the following steps: transducing Wharton jelly-derived mesenchymal stem cells by utilizing a lentiviral vector, so that the Wharton jelly-derived mesenchymal stem cells are over-expressed with Apelin and HBD3 proteins, then extracting engineered EVs, and loading the engineered EVs in GelMA hydrogel, so as to obtain Apelin-HBD3-EVs-coated GelMA. According to the Apelin-HBD3-EVs (at) GelMA compound, the anti-inflammatory and antibacterial characteristics of the Apelin-HBD3-EVs (at) GelMA are verified through in-vitro experiments and in-vivo experiments, and the Apelin-HBD3-EVs (at) GelMA compound shows excellent anti-inflammatory, antibacterial and wound healing promoting effects in an old mouse infectious wound model, and shows huge application prospects for coping with special challenges of chronic wound treatment of old people.